Quince Therapeutics, Inc.
General ticker "QNCX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $59.2M (TTM average)
Quince Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -20.4%.
Estimated limits based on current volatility of 8.6%: low 27.41$, high 32.56$
Factors to consider:
- Total employees count: 38 (+5.6%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Clinical trial failure, No resources to operate, Inability to raise capital, Labor/talent shortage/retention, Geopolitical risks
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [187.06$, 619.41$]
- 2026-12-31 to 2027-12-31 estimated range: [83.14$, 305.19$]
Financial Metrics affecting the QNCX estimates:
- Negative: with PPE of -3.7 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -38.19 <= 7.04
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
Short-term QNCX quotes
Long-term QNCX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $34.62MM | $57.28MM | $58.07MM |
| Operating Income | $-34.62MM | $-57.28MM | $-58.07MM |
| Non-Operating Income | $3.14MM | $1.22MM | $-22.70MM |
| R&D Expense | $9.45MM | $18.59MM | $35.38MM |
| Income(Loss) | $-31.48MM | $-56.06MM | $-80.77MM |
| Taxes | $-0.20MM | $0.09MM | $3.21MM |
| Net Income(Loss)* | $-31.28MM | $-56.15MM | $-83.98MM |
| Stockholders Equity | $85.08MM | $30.15MM | $-35.71MM |
| Assets | $167.90MM | $114.48MM | $93.52MM |
| Operating Cash Flow | $-18.29MM | $-31.90MM | $-41.42MM |
| Capital expenditure | $0.16MM | $0.26MM | $0.35MM |
| Investing Cash Flow | $-5.76MM | $21.91MM | $23.23MM |
| Financing Cash Flow | $0.14MM | $-4.78MM | $17.91MM |
| Earnings Per Share** | $-168.02 | $-259.59 | $-335.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.